首个白介素-17A和白介素-17F双重抑制剂bimekizumab的研究进展  

Research progress in bimekizumab,the first dual inhibitor of interleukin-17A and interleukin-17F

作　　者：张芳[1] 刘杰[1] 孙韬华[1] 赵艳[1] ZHANG Fang;LIU Jie;SUN Taohua;ZHAO Yan(Department of Pharmacy,Qingdao Municipal Hospital,Qingdao 266011,Shandong Province,China)

机构地区：[1]青岛市市立医院药学部,山东青岛266011

出　　处：《世界临床药物》2022年第3期336-341,共6页World Clinical Drug

基　　金：青岛市2018年度医药科研指导计划(2018-WJZD010)。

摘　　要：白介素-17(interleukin-17,IL-17)包括IL-17A、IL-17F等6种亚型,在多种免疫介导的疾病的发病机理中起重要作用。目前上市的IL-17A抑制剂对于银屑病(psoriasis),银屑病关节炎(psoriatic arthritis)和强直性脊柱炎(ankylosing spondylitis)均有良好疗效。bimekizumab(UCB4940)是由比利时优时比公司研发的一种新型人源化免疫球蛋白G1单克隆抗体,其能够与IL-17A和IL-17F上的特定位点选择性结合,同时对IL-17A和IL-17F效果产生抑制作用,从而产生比单独抑制IL-17A更为强大的抗炎效果。最新Ⅲ期临床研究数据显示bimekizumab治疗银屑病的效果确切,且耐受性好。该文对bimekizumab的药理学、药代动力学、临床疗效评价及安全性等情况作一概述。Interleukin (IL)-17,includes six subtypes such as IL-17A and IL-17F,plays an important role in the pathogenesis of a variety of immune-mediated diseases.The currently marketed IL-17A inhibitors have good effects on psoriasis,psoriatic arthritis and ankylosing spondylitis.Bimekizumab(UCB4940) is a noval humanized monoclonal immunoglobulin G1 antibody developed by Belgium’s Utimes Company,which is designed to selectively bind to specific sites on IL-17A and IL-17F,and simultaneously inhibiting both IL-17A and IL17F,thereby producing a stronger anti-inflammatory effect than inhibiting IL-17A alone.The latest phase Ⅲ clinical study data show that bimekizumab is effective in treating psoriasis and is well tolerated.This article reviewed the pharmacology,pharmacokinetics,clinical efficacy evaluation and safety of bimekizumab.

关 键 词：白介素-17 抑制剂 银屑病 强直性脊柱炎 bimekizumab 

分 类 号：R979.5[医药卫生—药品]